Dose homogeneity as a function of source activity in optimized I-125 prostate implant treatment plans

Citation
Wd. D'Souza et Rr. Meyer, Dose homogeneity as a function of source activity in optimized I-125 prostate implant treatment plans, INT J RAD O, 51(4), 2001, pp. 1120-1130
Citations number
18
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
ISSN journal
03603016 → ACNP
Volume
51
Issue
4
Year of publication
2001
Pages
1120 - 1130
Database
ISI
SICI code
0360-3016(20011115)51:4<1120:DHAAFO>2.0.ZU;2-2
Abstract
Purpose: In conventional treatment planning for permanent I-125 prostate im plants, it has been suggested that lower seed activities result in more hom ogeneous dose distributions and also less overdose of the critical structur es. We sought to determine if this hypothesis holds by analyzing treatment plans constructed using an automated optimized approach. Methods and Materials: We studied treatment plans for 10 patients using mix ed-integer programming and the branch-and-bound method. Two mixed-integer m odels (that yielded somewhat different treatment plans) were developed: a " basic" model and a "dose homogeneity" model. For each resulting treatment p lan, we examined dose homogeneity (by evaluating the dose non-uniformity ra tio [DNR] and the full-width half-maximum [FWHM] of the differential dose-v olume histogram [DVH]) as a function of three different source activities ( 0.35 mCi, 0.44 mCi, and 0.66 mCi). In addition, target coverage and critica l structure dose distributions were evaluated. Plans using multiple source activities were also evaluated for resulting dose inhomogeneities. Results: The homogeneity model results in a more homogeneous dose distribut ion than the basic model. DNR is lowered by an average of 42% (standard dev iation [SD] = 19%), 39% (SD = 21%), and 33% (SD = 21%) for the 0.35 mCi, 0. 44 mCi, and 0.66 mCi seeds, respectively, when the homogeneity model is emp loyed over the basic model. Corresponding average decreases in the FWHM of the DVH for 0.35 mCi, 0.44 mCi, and 0.66 mCi, respectively, are 29 Gy (SD = 28 Gy), 24 Gy (SD = 22 Gy), and 27 Gy (SD = 13 Gy). Seeds of 0.35 mCi and 0.44 mCi result in the lowest DNR and narrower FWHM of the DVH relative to 0.66 mCi seeds. In general, the 0.44 mCi seeds produce greater target cover age and require fewer seeds and needles than the 0.35 mCi seeds. Although 0 .66 mCi seeds result in the greatest target coverage, they yield highest cr itical structure doses. They also yield solutions requiring the least numbe r of seeds and needles. However, the dose distributions from 0.66 mCi seeds are highly inhomogeneous. Multiple source activities in the same treatment plan produce dose distributions that are comparable in homogeneity to 0.44 mCi seed implants. Conclusions: Even when an optimization model that seeks to minimize dose in homogeneity is employed, all factors involved in seed implants make 0.44 mC i the best activity choice in comparison with 0.35 mCi and 0.66 mCi. (C) 20 01 Elsevier Science Inc.